Currently, phase III clinicaltrials of sotagliflozin in T2DM patientsare ongoing, whereas this drug was recently approved by EMA (2019)in combination with insulin therapy in adults with T1DM and body massindex of at least 27 kg/m2, when insulin on its own doesnot achieve adequate glycemic control. Here, INS is linked to type 2 diabetes mellitus.